National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity TA1152 7 May 2026 7 May 2026 Zanidatamab for treating ...
The National Institute for Health and Care Excellence

Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families

The decision marks a significant milestone after both medicines were previously made available through managed access agreements while additional evidence on their effectiveness was gathered. SMA is a ...
The National Institute for Health and Care Excellence

New machines that keep donor livers alive outside the body could help hundreds waiting for a life-saving transplant

A consultation has begun on draft guidance recommending 4 specialist liver preservation machines for routine NHS use, which could help more of the 600 people in England waiting for a life-saving ...
National Institute for Health and Care Excellence

OpenAthens eligibility

Note: Healthcare students at universities which have an OpenAthens administrator can have an NHS OpenAthens account for the duration of their course. Students at these universities will have NHS ...
National Institute for Health and Care Excellence

Antimicrobial stewardship

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance. We've worked with Public Health England (PHE) to bring together our information on managing ...
National Institute for Health and Care Excellence

Quality statement 6: Emergency oxygen during an exacerbation

During an exacerbation, people with COPD may experience a worsening of gas exchange in the lungs, which can lead to low blood oxygen levels. Emergency oxygen is often given during the treatment of an ...
National Institute for Health and Care Excellence

Suspected sepsis: recognition, diagnosis and early management

This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or ...
National Institute for Health and Care Excellence

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
National Institute for Health and Care Excellence

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal ...